Get started
Author

Mark Andrew Landers

Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein
1994 · Anne-Marie B. Brillantes, Karol Ondrias, et al. · Cell · 853
Regulation of the large ( 1000 kb) imprinted murine Ube3a antisense transcript by alternative exons upstream of Snurf/Snrpn
2004 · M. Landers · Nucleic Acids Research · 152
Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer
2017 · Howard I. Scher, Ryon P. Graf, et al. · Cancer Research · 136
The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer
2015 · Himisha Beltran, Adam Jendrisak, et al. · Clinical Cancer Research · 136
Analytical Validation and Capabilities of the Epic CTC Platform: Enrichment-Free Circulating Tumour Cell Detection and Characterization
2015 · Shannon L. Werner, Ryon P. Graf, et al. · Journal of Circulating Biomarkers · 132
PDF
High Resolution Detection and Analysis of CpG Dinucleotides Methylation Using MBD-Seq Technology
2011 · Xun Lan, Christopher Adams, et al. · PLoS ONE · 82
Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival
2017 · Daniel J. Boffa, Ryon P. Graf, et al. · Cancer Epidemiology Biomarkers & Prevention · 71
Phenotypic diversity of circulating tumour cells in patients with metastatic castration‐resistant prostate cancer
2016 · Andrew S. McDaniel, Roberta Ferraldeschi, et al. · British Journal of Urology · 68
Maternal disruption of Ube3a leads to increased expression of Ube3a-ATS in trans
2005 · M. Landers · Nucleic Acids Research · 60
PDF
Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation Analysis
2016 · Stephanie B. Greene, Angel E. Dago, et al. · PLoS ONE · 56
PDF
Morphology-Predicted Large-Scale Transition Number in Circulating Tumor Cells Identifies a Chromosomal Instability Biomarker Associated with Poor Outcome in Castration-Resistant Prostate Cancer
2020 · Joseph D. Schonhoft, Jimmy L. Zhao, et al. · Cancer Research · 40
Genomic Analysis of Circulating Tumor Cells at the Single-Cell Level
2020 · Shan Lu, Chia-Jung Chang, et al. · Journal of Molecular Diagnostics · 33
An alignment algorithm for bisulfite sequencing using the Applied Biosystems SOLiD System
2010 · Brian D. Ondov, Charles Cochran, et al. · Bioinformatics · 26
PDF
Androgen receptor expression on circulating tumor cells in metastatic breast cancer
2017 · Takeo Fujii, James M. Reuben, et al. · PLoS ONE · 22
PDF
Correlation of FCGRT genomic structure with serum immunoglobulin, albumin and farletuzumab pharmacokinetics in patients with first relapsed ovarian cancer
2017 · Daniel J. O'Shannessy, Katie Bendas, et al. · Genomics · 19
PDF
Analytical Validation and Capabilities of the Epic CTC Platform: Enrichment-Free Circulating Tumour Cell Detection and Characterization
2015 · Shannon L. Werner, Ryon P. Graf, et al. · Journal of Circulating Biomarkers · 14
PDF
CTC enumeration and characterization as a pharmacodynamic marker in the phase I clinical study of APX3330, an APE1/Ref-1 inhibitor, in patients with advanced solid tumors.
2019 · Lincy Chu, Amanda K. L. Anderson, et al. · Journal of Clinical Oncology · 13
Detection and Characterization of Circulating Tumour Cells from Frozen Peripheral Blood Mononuclear Cells
2015 · David Lu, Ryon P. Graf, et al. · Journal of Circulating Biomarkers · 11
PDF
Identification and Characterization of Circulating Tumor Cells in Men Who have Undergone Prostatectomy for Clinically Localized, High Risk Prostate Cancer
2019 · Terence W. Friedlander, Christopher Welty, et al. · The Journal of Urology · 10
Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) and a circulating tumor cell (CTC) homologous recombination deficiency (HRD) phenotype or BRCA defects: A trial in progress.
2019 · Simon Chowdhury, Joaquin Mateo, et al. · Journal of Clinical Oncology · 5
AR-V7 and CTC heterogeneity biomarkers additively to predict patient (pt) outcomes with taxanes relative to approved AR targeted therapy.
2016 · Howard I. Scher, Ryon Graf, et al. · Journal of Clinical Oncology · 5
Phenotypic characterization of circulating tumor cells (CTCs) from neuroendocrine prostate cancer (NEPC) and metastatic castration-resistant prostate cancer (mCRPC) patients to identify a novel diagnostic algorithm for the presence of NEPC.
2015 · Himisha Beltran, Adam Jendrisak, et al. · Journal of Clinical Oncology · 5
Predictive biomarkers of sensitivity to androgen receptor signaling (ARS) and taxane-based chemotherapy in circulating tumor cells (CTCs) of patients (pts) with metastatic castration resistant prostate cancer (mCRPC).
2015 · Howard I. Scher, Jessica Louw, et al. · Journal of Clinical Oncology · 5
Analysis of circulating tumor cells (CTCs) in patients across multiple metastatic breast cancer (mBCa) cohorts identifies marked inter- and intra-patient heterogeneity in CTC size, shape, and overall morphology.
2018 · Gordon Vansant, Yipeng Wang, et al. · Journal of Clinical Oncology · 4
CTC phenotype classifier to identify mCRPC patients (pts) with high genomic instability CTCs and to predict failure of androgen ecreptor signaling (AR Tx) and taxane (T) systemic therapies.
2016 · Howard I. Scher, Adam Jendrisak, et al. · Journal of Clinical Oncology · 4
Works count: 101
Citation count: 1,996
H-index: 15
I10-index: 19
Year
Topic
Type